Synaptogenix Inc (SNPX)

[Cyosol]

That article mentions memantine discontinuation worsening cognitive decline, and yet every group in our trial improved except the severe patients on Bryo.

From the 2022 paper:

"As noted above, the #203 study showed a chance imbalance in the baseline SIB between treatment arms. Initial exploratory analyses showed that baseline SIB is statistically associated with both SIB score at 13 weeks post-randomization (Pearson’s ?=0.81, p<0.001) and the change in SIB scores at 13 weeks from baseline (Pearson’s ?=–0.25, p=0.014), suggesting that an imbalance in baseline SIB may confound the analyses."

For reference (Mean baseline +/- mean change (standard deviation)):

Moderate bryo: 83.0 + 3.94 (7.80)
Moderate placebo: 86.8 + 2.15 (4.78)

Severe bryo: 56.2 - 3.65 (7.42)
Severe placebo: 62.3 + 1.87 (15.26)

Take a look at those standard deviations and you'll immediately see why the real issue here is the small sample size, which is why they pooled the data to get a more accurate reading where placebo improvement drops to +1.17 (0.82).